Considering major BP have reviewed the abstract & typically takeovers follow convincing data post ASH conferences, a transaction of some kind could happen a lot sooner than some of us think.
We know Abbvie, BMS, and others were at the table and in discussions around cardio/breast cancer programs prior to DCB departure, now they’ve just reviewed AML synergies with absent toxicity.
If they could put 2+2 together as well as Mason can and draw correlation to FTO inhibition being the reason this combo was effective, I can’t see how they wouldn’t be writing up the paper work now. Why wait until Dec when there’s more eyes & competition.
- Forums
- ASX - By Stock
- RAC
- Ann: Impressive Bisantrene Phase 2 AML Clinical Results
Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-33
-
- There are more pages in this discussion • 199 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.50 |
Change
-0.025(1.64%) |
Mkt cap ! $258.9M |
Open | High | Low | Value | Volume |
$1.53 | $1.55 | $1.50 | $83.06K | 55.07K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6931 | $1.50 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.53 | 1846 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6931 | 1.495 |
1 | 6000 | 1.490 |
1 | 950 | 1.485 |
1 | 650 | 1.480 |
1 | 946 | 1.475 |
Price($) | Vol. | No. |
---|---|---|
1.500 | 900 | 1 |
1.525 | 1846 | 2 |
1.575 | 7705 | 1 |
1.580 | 6715 | 2 |
1.595 | 12136 | 1 |
Last trade - 13.15pm 20/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |